ABSTRACT
Background NVX-CoV2373 is a nanoparticle, protein-based COVID-19 vaccine. Individuals who are immunocompromised (IIC) are at high risk for infection and severe disease; however, real-world NVX-CoV2373 effectiveness data in IIC are limited.
Methods South Korean IIC aged ≥12 years who received a primary series, third dose, or fourth dose of NVX-CoV2373 were identified in The Korea Disease Control and Prevention Agency-COVID-19-National Health Insurance Service (K-COV-N) database. IIC were propensity score matched to non-immunocompromised (non-IC) individuals to minimize potential confounding. Outcomes were any and severe SARS-CoV-2 infections, collected in cumulative 30-day risk windows through 180 days post vaccination in primary series and third and fourth dose groups. Adjusted hazard ratios (aHRs) measured relative vaccine effectiveness by comparing IIC and non-IC individuals across dose groups, overall, and by immunocompromising condition.
Results A total of 755,727 doses of NVX-CoV2373 were administered to IIC February– December 2022, with 403,259 IIC included in this analysis. Through 180 days, aHRs (95% CI) for any SARS-CoV-2 infection were 1.10 (1.06–1.14), 1.05 (1.01–1.09), and 1.03 (1.02–1.05) for the primary series, third-dose, and fourth-dose groups; severe infection: 0.76 (0.52–1.12), 0.90 (0.53–1.51), and 1.11 (0.87–1.41), respectively. Risk estimates for any infection were relatively consistent across risk windows and among most immunocompromising conditions.
Conclusion NVX-CoV2373 provided similar protection among IIC and non-IC individuals regardless of dose administered and IC condition.
Competing Interest Statement
EG, SAC, KK, EB, and YJC are study investigators and do not have any conflicts of interest to report. JF, MHG, and MDR are employees of Novavax, Inc. and may own stock. MV was a salaried employee of Novavax, Inc. and may own stock.
Funding Statement
Funding was provided by Novavax, Inc.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol was approved by the Korea University Institutional Review Board (IRB No. 2023AN0124).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability
The data used in this study are from the K-CoV-N cohort, which is not publicly available. Researchers can apply for access to these data through the National Health Insurance Service (NHIS) and Korea Disease Control and Prevention (KDCA) data linkage system. Applications can be submitted via the Health Care Data Linkage (HCDL) website (https://hcdl.mohw.go.kr/) and are subject to review by the relevant authorities.
ABBREVIATIONS
- aHR
- adjusted hazard ratio;
- aSD
- absolute standardized difference;
- IC
- immunocompromised;
- ICU
- intensive care unit;
- IIC
- individuals who are immunocompromised;
- IR
- incidence rate;
- rS
- recombinant spike;
- rVE
- relative vaccine effectiveness;
- VE
- vaccine effectiveness.
